Catalyst Wire Dossier Catalyst Wire Dossier

ADXS31-142

· Advaxis, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ADXS31-142, covering 2024-02-20 to 2024-02-20. Get the full timeline:

Most recent: Clinical Trial Update: ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 1, Phase 2]

See pricing